Schrodinger SDGR Drug discovery — Revenue, Remaining Performance Obligation, Deferred Revenue

Other product segments

Similar metrics at other companies

VCYTBiopharmaceutical and other revenue — Deferred Revenue

$700K-58.8%

CNKOther Deferred Revenues — Revenue Remaining Performance Obligation

$272.6M+5.7%

TNLDeferred other revenue — Remaining performance obligations

$11M+175%

IDYAResearch And Development Services — Revenue Remaining Performance Obligation

$155.3M—

ABTPharmaceuticals — Remaining performance obligations

$258M—

TNLDeferred subscription revenue — Remaining performance obligations

$86M-2.3%

Questions, answered.

What is Schrodinger's drug discovery — revenue, remaining performance obligation, deferred revenue?

Schrodinger (SDGR) reported drug discovery — revenue, remaining performance obligation, deferred revenue of $95.17M in Q1 2026.

What does drug discovery — revenue, remaining performance obligation, deferred revenue mean?

This metric aggregates the total value of contracted revenue that remains to be recognized for services yet to be provided. It provides a comprehensive view of the company's total backlog and future revenue potential from existing customer agreements.